Proteinuria 

  • Author: Edgar V Lerma, MD, FACP, FASN, FAHA; Chief Editor: Vecihi Batuman, MD, FACP, FASN   more...
 
Updated: Jan 31, 2012
 

Background

Plasma proteins are essential components of any living being. The kidneys play a major role in the retention of plasma proteins, and this is accomplished by the renal tubules through their reabsorption of such proteins as they pass through the glomerular filtration barrier. Normal urine protein excretion is up to 150 mg/d. Therefore, the detection of abnormal quantities or types of protein in the urine is considered an early sign of significant renal or systemic disease.

The detection of various types of proteins excreted in the urine has been extensively used in the assessment of renal diseases. The detection of low levels of albumin excretion (termed microalbuminuria) has been linked to the identification of the early stages of diabetic kidney disease.

Normally, the concentration of albumin in the urine is less than 5 mg/L. When expressed as an excretion rate (ie, urine albumin excretion rate [UAER]), this concentration averages 2.6-12.6 µg/min in males and 1.1-21.9 µg/min in females. Microalbuminuria is referred to as excretion of 30-300 mg/d or 20-200 µg/min of albumin, which, by routine dipstick screening methods, is too small to be detected.

To date, numerous assays have been developed to detect this range of concentration of albumin in the urine. However, most of these assays are limited by intraindividual variations, such as physical activity level, acute illnesses or fevers, menstruation, pregnancy, vaginal discharge, diet, blood pressure, volume status, degree of glycemic control, and urine collection method (eg, 24 h, overnight or timed, short-term). On average, albumin excretion is 25% higher during the day than overnight, with a day-to-day variation of 40%. Therefore, before a patient is classified as having microalbuminuria, at least 3 urine samples over a 6-month period that satisfy the above range criterion are recommended.

Recent studies

In a study of 225 proteinuric patients with diabetes mellitus type 2, Chiu et al investigated whether vascular calcification, which can be particularly severe in nondialyzed patients with coexisting proteinuria and diabetes, is a prognostic indicator in early stage type 2 diabetic nephropathy. Eighty-six percent of the study's patients were found to have coronary artery calcification, the degree of which, the authors determined, was associated with older age, white ethnicity, and being male. (Fifty-four patients died during the follow-up period, which averaged 39 months.) Univariate and multivariate analyses indicated that the degree of coronary artery calcification was, in relation to the calcification's severity, an independent predictor of all-cause mortality in the study's patients, with a 2.5-fold greater mortality risk found in subjects with a calcification score in the highest quartile.[1]

Next

Pathophysiology

The presence of abnormal amounts or types of protein in the urine reflects the following:

  • Systemic diseases that result in an inability of the kidneys to normally reabsorb the proteins through the renal tubules
  • Overproduction of plasma proteins that are capable of passing through the normal glomerular basement membrane (GBM), as they enter the tubular fluid in amounts that exceed the capacity of the normal proximal tubule to reabsorb them
  • A defective glomerular barrier that allows abnormal amounts of proteins of intermediate molecular weight to enter the Bowman space
Previous
Next

Epidemiology

Frequency

United States

Approximately 4% of males and 7% of females have proteinuria detected by a single routine dipstick test. The vast majority of these cases are due to transient proteinuria, which resolves spontaneously and does not represent significant underlying renal disease. Proteinuria is found upon repeat testing in 21% of males and 7% of females.

Mortality/Morbidity

  • Filtration of albumin and nonalbumin proteins across the abnormal glomerular capillary wall (GCW) exposes mesangial cells and tubular cells to these proteins. Albumin and nonalbumin proteins are normally reabsorbed from the glomerular filtrate in the proximal convoluted tubule (PCT).
  • Heavy proteinuria may exceed the capacity of lysosomes in the PCT cells to metabolize reabsorbed protein, and toxic enzymes may leak into the cells and the surrounding renal interstitium[2] as a consequence of lysosomal degranulation. Whether the nephrotoxic protein is albumin, nonalbumin protein, or both remains unclear. Other proteins, such as transferrin, complement components, and low-density lipoproteins, also appear to be directly toxic to tubular cells. Lipoproteins also appear to be toxic to mesangial cells and may contribute to the development of glomerular sclerosis. A consequence of protein-mediated cytotoxicity is the production of chemokines and cytokines that initiate an inflammatory response and ultimately lead to sclerosis and fibrosis.
  • In addition to being a predictor of outcome in patients with renal disease, microalbuminuria also is a predictor of morbidity and mortality in patients who do not have evidence of significant renal disease. In patients with hypertension, the presence of microalbuminuria is correlated to the presence of left ventricular hypertrophy. In hypertensive patients and normotensive patients, the presence of microalbuminuria predicts an increased risk of cardiovascular morbidity and mortality.
  • In a study of 2310 patients, Jackson et al examined the prognostic value of spot urinary-to-creatinine ratios (UACRs) in persons with heart failure.[3] The authors determined that compared with patients with normoalbuminuria, individuals with an increased UACR tended to be older, had higher rates of cardiovascular comorbidity and diabetes mellitus, and suffered from worse renal function. However, even after adjustment for variables such as renal function and diabetes, it was determined that an increased UACR was associated with a greater mortality risk. The authors concluded that elevated UACR has significant value as a prognostic indicator for patients with heart failure.

Race

Many causes of proteinuria are more common in African Americans and other groups.

  • Diabetic nephropathy is more common in American Indians, African Americans, and Hispanics.
  • The primary glomerular disorder, focal segmental glomerulosclerosis, also is more common in African Americans.
  • In general, African Americans have a higher incidence and tend to have more rapid progression of glomerular diseases and, hence, proteinuria.
  • In a study by Friedman et al, nondiabetic chronic kidney disease was found to occur in more than 3 million African Americans who have genetic variants in both copies of APOL1, increasing their risk for hypertension-attributable end-stage renal disease and focal segmental glomerulosclerosis. However, African Americans without the risk genotype appear to have a similar risk for developing nondiabetic chronic kidney disease as European Americans.[4]

Sex

Most primary glomerular diseases associated with proteinuria (eg, membranous glomerulonephritis) and secondary renal diseases (eg, diabetic nephropathy) are more common in males than in females. As a result, persistent proteinuria is at least twice as common in males as in females.

Age

The incidence of hypertension and diabetes increases with age, and, as a consequence, the incidence of persistent proteinuria (and microalbuminuria) also increases with age.

Previous
 
 
Contributor Information and Disclosures
Author

Edgar V Lerma, MD, FACP, FASN, FAHA  Clinical Associate Professor of Medicine, Section of Nephrology, Department of Medicine, University of Illinois at Chicago College of Medicine; Research Director, Internal Medicine Training Program, Advocate Christ Medical Center; Consulting Staff, Associates in Nephrology, SC

Edgar V Lerma, MD, FACP, FASN, FAHA is a member of the following medical societies: American Heart Association, American Medical Association, American Society of Hypertension, American Society of Nephrology, Chicago Medical Society, Illinois State Medical Society, National Kidney Foundation, and Society of General Internal Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Kevin McLaughlin  MB, ChB, MSc, PhD, Associate Professor, Assistant Dean, Department of Medicine, University of Calgary Faculty of Medicine, Calgary Health Region

Kevin McLaughlin is a member of the following medical societies: American Society of Nephrology, American Society of Transplantation, and College of Physicians and Surgeons of Alberta

Disclosure: Nothing to disclose.

Specialty Editor Board

Frank C Brosius III, MD  Nephrology Program Director, Professor of Internal Medicine and Physiology, Department of Internal Medicine, Division of Nephrology, University of Michigan School of Medicine

Frank C Brosius III, MD is a member of the following medical societies: Alpha Omega Alpha, American Diabetes Association, American Society of Nephrology, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

George R Aronoff, MD  Director, Professor, Departments of Internal Medicine and Pharmacology, Section of Nephrology, Kidney Disease Program, University of Louisville School of Medicine

George R Aronoff, MD is a member of the following medical societies: American Federation for Medical Research, American Society of Nephrology, Kentucky Medical Association, and National Kidney Foundation

Disclosure: Nothing to disclose.

Rebecca J Schmidt, DO, FACP, FASN  Professor of Medicine, Section Chief, Department of Medicine, Section of Nephrology, West Virginia University School of Medicine

Rebecca J Schmidt, DO, FACP, FASN is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Nephrology, International Society of Nephrology, National Kidney Foundation, Renal Physicians Association, and West Virginia State Medical Association

Disclosure: Renal Ventures Ownership interest Other

Chief Editor

Vecihi Batuman, MD, FACP, FASN  Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Medicine Service, Southeast Louisiana Veterans Health Care System

Vecihi Batuman, MD, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, and International Society of Nephrology

Disclosure: Nothing to disclose.

References
  1. Chiu YW, Adler SG, Budoff MJ, et al. Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int. Mar 17 2010;[Medline].

  2. Wu Y, Chen Y, Chen D, et al. Presence of foam cells in kidney interstitium is associated with progression of renal injury in patients with glomerular diseases. Nephron Clin Pract. Aug 12 2009;113(3):c155-c161. [Medline].

  3. Jackson CE, Solomon SD, Gerstein HC, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. Aug 15 2009;374(9689):543-50. [Medline].

  4. Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR. Population-Based Risk Assessment of APOL1 on Renal Disease. J Am Soc Nephrol. Nov 2011;22(11):2098-105. [Medline].

  5. Hladunewich MA, Troyanov S, Calafati J, et al. The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol. Aug 6 2009;[Medline].

  6. Hebert LA, Birmingham DJ, Shidham G, et al. Random spot urine protein/creatinine ratio is unreliable for estimating 24-Hour proteinuria in individual systemic lupus erythematosus nephritis patients. Nephron Clin Pract. Aug 12 2009;113(3):c177-c182. [Medline].

  7. Methven S, Macgregor MS, Traynor JP, et al. Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio. Nephrol Dial Transplant. Mar 17 2010;[Medline].

  8. Cirillo M. Evaluation of glomerular filtration rate and of albuminuria/proteinuria. J Nephrol. Mar-Apr 2010;23(2):125-32. [Medline].

  9. Roozbeh J, Banihashemi MA, Ghezlou M, et al. Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy. Ren Fail. Jan 2010;32(2):172-8. [Medline].

  10. Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res. Aug 7 2009;[Medline].

  11. Vegter S, Perna A, Postma MJ, et al. Sodium Intake, ACE Inhibition, and Progression to ESRD. J Am Soc Nephrol. Jan 2012;23(1):165-73. [Medline].

  12. Robles NR, Romero B, de Vinuesa EG, et al. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail. Jan 2010;32(2):192-7. [Medline].

  13. Burton C, Harris KP. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis. Jun 1996;27(6):765-75. [Medline].

  14. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. ALYSIS. Sep 1 1997;127(5):337-45. [Medline].

  15. Klahr S, Levey AS, Beck GJ. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. Mar 31 1994;330(13):877-84. [Medline].

  16. Lewis EJ, Hunsicker LG, Bain RP. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [published erratum appears in N Engl J Med 1993 Jan 13;330(2):152]. N Engl J Med. Nov 11 1993;329(20):1456-62. [Medline].

  17. Robinson RR. Isolated proteinuria in asymptomatic patients. Kidney Int. Sep 1980;18(3):395-406. [Medline].

  18. Ruggenenti P, Perna A, Mosconi L. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int Suppl. Dec 1997;63:S54-7. [Medline].

  19. Springberg PD, Garrett LE Jr, Thompson AL Jr. Fixed and reproducible orthostatic proteinuria: results of a 20-year follow-up study. Ann Intern Med. Oct 1982;97(4):516-9. [Medline].

  20. Waugh NR, Robertson AM. Protein restriction in diabetic renal disease. In: The Cochrane Database of Systematic Reviews [serial CD-ROM]. Issue 4. 1999.

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.